Interventions of Interest The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost-effectiveness if priced between $143,900 to $273,700 per treatment cycle. Final Documents For questions or to request a Spanish translated Report-at-a-Glance or ICER […]
Interventions of Interest: Rucaparib (Rubraca®, Clovis Oncology) Niraparib (Zejula®, Tesaro, Inc.) Olaparib (Lynparza®, AstraZeneca) ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. During the public meeting the Midwest CEPAC voted on key questions related to the clinical effectiveness and value of the […]
Intervention of interest: Computed tomography (CT) colonography Conventional colonoscopy Computed tomography colonography (CT colonography or CTC) is a minimally invasiveradiological technique used to provide images of the colon and rectum. CTC has been suggested as an alternative or as complementary to conventional colonoscopy and other population-based screening methods for colorectal cancer. Given that only 40%-60% […]
Prostate cancer is the second leading cause of cancer deaths and the seventh overall cause of death in men in the United States (Centers for Disease Control and Prevention, 2008). Given that most new cases are diagnosed at an early, localized stage, significant attention has been focused on understanding the risks and benefits of alternative […]
This report examines the comparative effectiveness and value of screening options for women with dense breast tissue, including hand-held and automated breast ultrasound, digital breast tomosynthesis (DBT), and magnetic resonance imaging (MRI). The CTAF Panel voted that the evidence supports supplemental screening of women at high risk for breast cancer, and that screening with MRI, among commonly used screening […]
Interventions of interest: Hand-held and automated breast ultrasound Digital breast tomosynthesis (DBT) Magnetic resonance imaging (MRI) Following a negative mammogram, many women with dense breast tissue face a decision: whether to receive additional screening, and if so, what modality to use. Many mammography facilities are now informing women with dense breasts about the potential for […]
Interventions of interest: Hand-held and automated breast ultrasound Digital breast tomosynthesis (DBT) Magnetic resonance imaging (MRI) Following a negative mammogram, many women with dense breast tissue face a decision: whether to receive additional screening, and if so, what modality to use. Many mammography facilities are now informing women with dense breasts about the potential for […]
Interventions of Interest: tisagenlecleucel (KymriahTM , Novartis) axicabtagene ciloleucel (YescartaTM, Kite Pharma) ICER developed a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. The policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit there will be changes needed in future pricing, payment, and […]
Interventions of Interest: Carfilzomib (Kyprolis®, Onyx) Daratumumab (Darzalex®, Janssen Bitoech) Elotuzumab (Empliciti®, Bristol MeyersSquibb) Ixazomib (Ninlaro®, Takeda) Panobinostat (Farydak®, Novartis Pharmaceuticals Corp.) Pomalidomide (Pomalyst®, Celgene) Multiple myeloma is a cancer of the blood in which the bone marrow produces a high number of cancerous plasma cells. The excessive growth of plasma cells can cause bone […]
Interventions of Interest: Tyrosine kinase inhibitors: Afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceuticals, Inc.) Erlotinib (Tarceva®, Genentech, Inc. and Astellas Pharma US, Inc.) Gefitinib (Iressa®, AstraZeneca) Immunotherapies targeting the programmed death 1 (PD-1) receptor or its ligand (PD-L1): Atezolizumab (Tecentriq®, Genentech, Inc., Roche Group) Nivolumab (Opdivo®, Bristol-Meyers Squibb Co.) Pembrolizumab (Keytruda®, Merck & Co.) Lung cancer is […]